Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts

Cancer Science

Volumn 103, Issue 2, 2012, Pages 310-316

  Iwase, Yuko ^a   Maitani, Yoshie ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROCAMPTOTHECIN; CAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN; LIGAND; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER SURVIVAL; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EXPERIMENTAL NEOPLASM; FEMALE; HEART; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPLEEN; SURVIVAL; THYROID MEDULLARY CARCINOMA; TUMOR CELL; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; HUMANS; LIPOSOMES; MICE; OCTREOTIDE; PHOSPHORYLATION; RECEPTORS, SOMATOSTATIN; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856480241     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02128.x     Document Type: Article

References (30)

1. Zatelli MC, Tagliati F, Taylor JE et al. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J Clin Endocrinol Metab 2001; 86: 2161-9.
2. Zatelli MC, Tagliati F, Taylor JE et al. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res 2002; 5: 229-33.
3. Mato E, Matias-Guiu X, Chico A et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clini Endocrinol Metab 1998; 83: 2417-20.
4. Strock CJ, Park JI, Rosen DM et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 2006; 91: 79-84.
5. Koga K, Hattori Y, Komori M et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci 2010; 101: 941-7.
6. Kawato Y, Aonuma M, Hirota Y et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-91.
7. Kawato Y, Furuta T, Aonuma M et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192-8.
8. Hsiang YH, Wu HY, Liu LF. Topoisomerases: novel therapeutic targets in cancer chemotherapy. Biochem Pharmacol 1988; 37: 1801-2.
9. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-6.
10. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
11. Lavelle F, Bissery MC, Andre S et al. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996; 23: 11-20.
12. Grozinsky-Glasberg S, Shimon I, Korbonits M et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr-Relat Cancer 2008; 15: 701-20.
13. Iwase Y, Maitani Y. Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma. Mol Pharm 2011; 8: 330-7.
14. Matsumura Y, Maeda HA. New concept for macromolecular therapeutics in cancer chemotherapy mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
15. Grozinsky-Glasberg S, Franchi G, Teng M et al. Octreotide and the mTOR inhibitor RAD001 (Everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumor cell line. Neuroendocrinolgy 2008; 87: 168-81.
16. Su JC, Tseng CL, Chang TG et al. A synthetic method for peptide-PEG-lipid conjugates: application of Octreotide-PEG-DSPE synthesis. Bioorg Med Chem Let 2008; 18: 4593-6.
17. Hattori Y, Shi L, Ding W et al. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release 2009; 136: 30-7.
18. Guichard S, Terret C, Hennebelle I et al. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999; 80: 364-70.
19. Hattori Y, Yoshizawa T, Koga K et al. NaCl induced high cationic hydroxyethylated cholesterol-based nanoparticle-mediated synthetic small interfering RNA transfer into prostate carcinoma PC-3 cells. Biol Pharm Bull 2008; 31: 2294-301.
20. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-64.
21. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-41.
22. Vasko V, Saji M, Hardy E et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004; 41: 161-70.
23. Bellacosa A, Kumar CC, Di Cristofano A et al. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
24. Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 2007; 282: 3571-83.
25. McManus EJ, Alessi DR. TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nature Cell Biol 2002; 4: E214-16.
26. Rivory LP, Bowles MR, Robert J et al. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996; 52: 1103-11.
27. Lamberts SWJ, Lery AJ, Herder WW et al. Octreotide. Drug Therapy 1996; 334: 246-54.
28. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252-61.
29. Modigliani E, Cohen R, Joannidis S et al. Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 1992; 36: 183-6.
30. Lupoli G, Cascone E, Arlotta F et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 1996; 78: 1114-8.